Review: Chemotherapy in newly diagnosed primary central nervous system lymphoma

Therapeutic Advances in Medical Oncology

Volumn 2, Issue 4, 2010, Pages 273-292

  Hashemi Sadraei, Nooshin ^a   Peereboom, David M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

blood brain barrier disruption; chemotherapy; high dose chemotherapy; intra arterial chemotherapy; intraocular chemotherapy; intrathecal chemotherapy; methotrexate; neurocognitive toxicity; primary central nervous system lymphoma

Indexed keywords

BUSULFAN; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; IFOSFAMIDE; LOMUSTINE; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PACLITAXEL; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE; TENIPOSIDE; THIOTEPA; TROFOSFAMIDE; VINBLASTINE; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD BRAIN BARRIER; BLOOD RETINA BARRIER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INFILTRATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CATARACT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CORNEA DISEASE; DEMENTIA; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRY EYE; ENDOPHTHALMITIS; GAIT DISORDER; GLAUCOMA; HEPATITIS; HUMAN; ILEUS; IMMUNOCOMPETENCE; INTRAOCULAR TUMOR; KERATOPATHY; KIDNEY DYSFUNCTION; LEUKOENCEPHALOPATHY; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NEOVASCULAR GLAUCOMA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RETINA MACULOPATHY; RETINOPATHY; REVIEW; SEIZURE; SEPSIS; STROKE; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; VEIN THROMBOSIS; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

EID: 78649232906     PISSN: 17588340     EISSN: None     Source Type: Journal    
DOI: 10.1177/1758834010365330     Document Type: Review

References (98)

1. Abrey, L.E., Ben-Porat, L., Panageas, K.S., Yahalom, J., Berkey, B., Curran, W. et al. (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24: 5711-5715.
2. Abrey, L.E., de Angelis, L.M. and Yahalom, J. ( 1998) Long-term survival in primary CNS lymphoma. J Clin Oncol 16: 859-863.
3. Abrey, L.E., Moskowitz, C.H., Mason, W.P., Crump, M., Stewart, D., Forsyth, P. et al. (2003) Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 21: 4151-4156.
4. Abrey, L.E., Yahalom, J. and de Angelis, L.M. ( 2000) Treatment for primary CNS lymphoma: the next step. J Clin Oncol 18: 3144-3150.
5. Angelov, L., Doolittle, N.D., Kraemer, D.F., Siegal, T., Barnett, G.H., Peereboom, D.M. et al. (2009) Blood-brain barrier disruption and intra-arterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 27: 3503-3509.
6. Balis, F.M. and Poplack, D.G. ( 1989) Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 11: 74-86.
7. Batchelor, T., Carson, K., O'Neill, A., Grossman, S.A., Alavi, J., New, P. et al. (2003 a) Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 21: 1044-1049.
8. Batchelor, T.T., Kolak, G., Ciordia, R., Foster, C.S. and Henson, J.E. ( 2003b) High-dose methotrexate for intraocular lymphoma. Clin Cancer Res 9: 711-717.
9. Baumann, M.A., Ritch, P.S., Hande, K.R., Williams, G.A., Topping, T.M. and Anderson, T. ( 1986) Treatment of intraocular lymphoma with high-dose Ara-C. Cancer 57: 1273-1275.
10. Blay, J.Y., Conroy, T., Chevreau, C., Thyss, A., Quesnel, N., Eghbali, H. et al. (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 16: 864-871.
11. Borsi, J.D. and Moe, P.J. ( 1987) A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g / m 2 in children with acute lymphoblastic leukemia. Cancer 60: 5-13.
12. Brevet, M., Garidi, R., Gruson, B., Royer, B., Vaida, I. and Damaj, G. ( 2005) First-line autologous stem cell transplantation in primary CNS lymphoma. Eur J Haematol 75: 288-292.
13. Buggage, R.R., Chan, C.C. and Nussenblatt, R.B. ( 2001) Ocular manifestations of central nervous system lymphoma. Curr Opin Oncol 13: 137-142.
14. Cbtrus (2009) http://www.cbtrus.org/2009-npcr/tables/Table5.pdf (accessed 25 January 2010).
15. Char, D.H., Ljung, B.M., Miller, T. and Phillips, T. ( 1988) Primary intraocular lymphoma (ocular reticulum cell sarcoma) diagnosis and management. Ophthalmology 95: 625-630.
16. Colombat, P., Lemevel, A., Bertrand, P., Delwail, V., Rachieru, P., Brion, A. et al. (2006) High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38: 417-420.
17. Correa, D.D., de Angelis, L.M., Shi, W., Thaler, H., Glass, A., Abrey, L.E. et al. (2004) Cognitive functions in survivors of primary central nervous system lymphoma. Neurology 62: 548-555.
18. Correa, D.D., Rocco-Donovan, M., de Angelis, L.M., Dolgoff-Kaspar, R., Iwamoto, F., Yahalom, J. et al. (2009) Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 91: 315-321.
19. Crossen, J.R., Garwood, D., Glatstein, E. and Neuwelt, A. ( 1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 12: 627-642.
20. Crossen, J.R., Goldman, D.L., Dahlborg, S.A. and Neuwelt, E.A. ( 1992) Neuropsychological assessment outcomes of nonacquired immunodeficiency syndrome patients with primary central nervous system lymphoma before and after blood-brain barrier disruption chemotherapy. Neurosurgery 30: 23-29.
21. Dahlborg, S.A., Henner, W.D., Crossen, J.R., Tableman, C.M., Petrillo, A., Braziel, R. et al. (1996) Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2: 166-174.
22. de Angelis, L.M., Seiferheld, W., Schold, S.C., Fisher, B. and Schultz, C. ( 2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 20: 4643-4648.
23. de Angelis, L.M., Yahalom, J., Thaler, H.T. and Kher, U. ( 1992) Combined modality therapy for primary CNS lymphoma. J Clin Oncol 10: 635-643.
24. de Smet, M.D., Stark-Vancs, V., Kohler, D.R., Smith, J., Wittes, R. and Nussenblatt, R.B. ( 1996) Am J Ophthalmol 121: 442-444.
25. de Smet, M.D., Stark-Vancs, V., Kohler, D., Solomon, D. and Chan, C.C. (1999) Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol 83: 448-451.
26. Doolittle, N.D., Miner, M.E., Hall, W.A., Siegal, T., Jerome, E., Osztie, E. et al. (2000) Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer 88: 637-647.
27. Dukic, S.F., Heurtaux, T., Kaltenbach, M.L., Hoizey, G., Lallemand, A. and Vistelle, R. ( 2000) Influence of schedule of administration on methotrexate penetration in brain tumours. Eur J Cancer 36: 1578-1584.
28. Ekenel, M., Iwamoto, F.M., Ben-Porat, L.S., Panageas, K.S., Yahalom, J., de Angelis, L.M. et al. (2008) Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 113: 1025-1031.
29. Ettinger, L.J., Chervinsky, D.S., Freeman, A.I. and Creaven, P.J. ( 1982) Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma. Cancer 50: 1676-1682.
30. Ewing, J.R., Brown, S.L., Lu, M., Panda, S., Ding, G., Knight, R.A. et al. (2006) Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab 26: 310-320.
31. Fazekas, F., Chawluk, J.B., Alavi, A., Hurtig, H.I. and Zimmerman, R.A. ( 1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJNR Am J Neuroradiol 8: 421-426.
32. Ferreri, A.J., Blay, J.Y., Reni, M., Pasini, F., Gubkin, A., Tirelli, U. et al. (2002 a) Relevance of intraocular involvement in the management of primary central nervous system lymphomas. Ann Oncol 13: 531-538.
33. Ferreri, A.J., Blay, J.Y., Reni, M., Pasini, F., Spina, M., Ambrosetti, A. et al. (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21: 266-272.
34. Ferreri, A.J., Reni, M., Foppoli, M., Martelli, M., Pangalis, G.A., Frezzato, M. et al. (2009) High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 374: 1512-1520.
35. Ferreri, A.J., Reni, M., Pasini, F., Calderoni, A., Tirelli, U., Pivnik, A. et al. (2002 b) A multicenter study of treatment of primary CNS lymphoma. Neurology 58: 1513-1520.
36. Ferreri, A.J., Crocchiolo, R., Assanelli, A., Govi, S. and Reni, M. ( 2008) High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leukemia Lymphoma 11: 2042-2047.
37. Fishburne, B.C., Wilson, D.J., Rosenbaum, J.T. and Neuwelt, E. ( 1997) Intravitreal methotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 115: 1152-1156.
38. Fliessbach, K., Helmstaedter, C., Urbach, H., Althaus, A., Pels, H., Linnebank, M. et al. (2005) Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 64: 1184-1188.
39. Fliessbach, K., Urbach, H., Helmstaedter, C., Pels, H., Glasmacher, A., Kraus, J.A. et al. (2003) Cognitive performance and MRI findings after high-dose systemic and intraventricular chemotherapy for primary CNS lymphoma. Arch Neurol 60: 563-568.
40. Frenkel, S., Hendler, K., Siegal, T., Shalom, E. and Pe'er, J. ( 2008) Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthal 92: 383-388.
41. Gavrilovic, I.T., Hormigo, A., Yahalom, J., de Angelis, L.M. and Abrey, L.E. ( 2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 24: 4570-4574.
42. Gerstner, E.R., Carson, K.A., Grossman, S.A. and Batchelor, T.T. ( 2008) Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiation. Neurology 70: 401-402.
43. Grimm, S.A., McCannel, C.A., Omuro, A.M., Ferreri, A.J., Blay, J.Y., Neuwelt, E.A. et al. (2008) Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurol 71: 1355-1360.
44. Grimm, S.A., Pulido, J.S., Jahnke, K., Schiff, D., Hall, A.J., Shenkier, T.N. et al. (2007) Primary intraocular lymphoma: an International Primary Central Nervous System Lymphoma Collaborative Group Report. Ann Oncol 18: 1851-1855.
45. Guha-Thakurta, N., Damek, D., Pollack, C. and Hochberg, F.H. ( 1999) Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 43: 259-268.
46. Gunduz, K., Pulido, J.S., McCannel, C.A. and O'Neill, B.P. ( 2006) Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus 21: E9.
47. Harder, H., Holtel, H., Bromberg, J.E.C., Poortmans, P., Haaxma-Reiche, H., KluinNelemans, H. et al. (2004) Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology 62: 544-555.
48. Herrlinger, U., Kuker, W., Uhl, M., Blaicher, H.P., Karnath, H.O., Kanz, L. et al. (2005) NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. Ann Neurol 57: 843-847.
49. Herrlinger, U., Schabet, M., Brugger, W., Kortmann, R.D., Küker, W., Deckert, M. et al. (2002) German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 51: 247-252.
50. Hiraga, S., Arita, N., Ohnishi, T., Kohmura, E., Yamamoto, K., Oku, Y. et al. (1999) Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 91: 221-230.
51. Hoang-Xuan, K., Taillandier, L., Chinot, O., Soubeyran, P., Bogdhan, U., Hildebrand, J. et al. (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21: 2726-2731.
52. Hormigo, A., Abrey, L., Heinemann, M.H. and de Angelis, L.M. ( 2004) Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126: 202-208.
53. Illerhaus, G., Marks, R., Ihorst, G., Guttenberger, R., Ostertag, C., Derigs, G. et al. (2006) High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 24: 3865-3870.
54. Illerhaus, G., Marks, R., Müller, F., Ihorst, G., Feuerhake, F., Deckert, M. et al. (2009) High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20: 319-325.
55. Illerhaus, G., Müller, F., Feuerhake, F., Schäfer, A.O., Ostertag, C. and Finke, J. ( 2008) High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 93: 147-148.
56. Isobe, K., Ejima, Y., Tokumaru, S., Shikama, N., Suzuki, G., Takemoto, M. et al. (2006) Treatment of primary intraocular lymphoma with radiation therapy: a multi-institutional survey in Japan. Leuk Lymphoma 47: 1800-1805.
57. Itty, S., Olson, J.H., O'Connell, D.J. and Pulido, J.S. ( 2009) Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and / or radiotherapy. Retina 29: 415-416.
58. Jahnke, K., Korfel, A., Martus, P., Weller, M., Herrlinger, U., Schmittel, A. et al. (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16 (3): 445-449.
59. Jahnke, K., Doolittle, N.D., Muldoon, L.L. and Neuwelt, E.A. ( 2006a) Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurg Focus 21: E11.
60. Jahnke, K., Korfel, A., Komm, J., Bechrakis, N.E., Stein, H., Thiel, E. et al. (2006 b) Intraocular lymphoma 2000-2005: results of a retrospective multi-centre trial. Graefes Arch Clin Exp Ophthalmol 244: 663-669.
61. Jahnke, K., Korfel, A., Martus, P., Weller, M., Herrlinger, U., Schmittel, A. et al. (2005 a) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16: 445-449.
62. Jahnke, K., Thiel, E., Abrey, L.E., Neuwelt, E.A. and Korfel, A. ( 2007) Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol 1: 247-258.
63. Jahnke, K., Wagner, T., Bechrakis, N.E., Willerding, G., Coupland, S.E., Fischer, L. et al. (2005 b) Pharmacokinetics and efficacy of ifosfamide or trofosfamide in patients with intraocular lymphoma. Ann Oncol 16: 1974-1978.
64. Khan, R.B., Shi, W., Thaler, H.T., de Angelis, L.M. and Abrey, L.E. ( 2002) Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma? J Neurooncol 58: 175-178.
65. Kitzmann, A.S., Pulido, J.S., Mohney, B.G., Baratz, K.H., Grube, T., Marler, R.J. et al. (2007) Intraocular use of rituximab. Eye 21: 1524-1527.
66. Mason, J.O. and Fischer, D.H. ( 2003) Intrathecal chemotherapy for recurrent central nervous system intraocular lymphoma. Ophthalmology 110: 1241-1244.
67. McAllister, L.D., Doolittle, N.D., Guastadisegni, P.E., Kraemer, D.F., Lacy, C.A., Crossen, J.R. and Neuwelt, E.A. ( 2000) Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma. Neurosurgery 46: 51-60.
68. Montemurro, M., Kiefer, T., Schuler, F., Al-Ali, H.K., Wolf, H.H., Herbst, R. et al. (2007) Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 18: 665-671.
69. Morris, P.G. and Abrey, L.E. (2009) Therapeutic challenges in primary CNS lymphoma. Lancet Neurol 8: 581-592.
70. Muldoon, L.L., Soussain, C., Jahnke, K., Johanson, C., Siegal, T., Smith, Q.R. et al. (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25: 2295-2305.
71. Nelson, D.F., Martz, K.L., Bonner, H., Nelson, J.S., Newall, J., Kerman, H.D. et al. (1992) Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23: 9-17.
72. Neuwelt, E.A., Diehl, J.T., Vu, L.H., Hill, S.A., Michael, A.J. and Frenkel, E.P. ( 1981) Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94: 449-454.
73. Neuwelt, E.A., Frenkel, E.P., Rapoport, S. and Barnett, P. ( 1980) Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery 7: 36-43.
74. Neuwelt, E.A., Goldman, D.L., Dahlborg, S.A., Crossen, J., Ramsey, F., Roman-Goldstein, S. et al. (1991) Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 9: 1580-1590.
75. Neuwelt, E.A., Guastadisegni, P.E., Várallyay, P. and Doolittle, N.D. ( 2005) Imaging changes and cognitive outcome in primary CNS lymphoma after enhanced chemotherapy delivery. AJNR Am J Neuroradiol 26: 258-265.
76. Omuro, A.M., Ben-Porat, L.S., Panageas, K.S., Kim, A.K., Correa, D.D., Yahalom, J. et al. (2005 a) Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol 62: 1595-1600.
77. Omuro, A.M., de Angelis, L.M., Yahalom, J. and Abrey, L.E. ( 2005b) Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. Neurology 64: 69-74.
78. Omuro, A.M., Taillandier, L., Chinot, O., Carnin, C., Barrie, M. and Hoang-Xuan, K. ( 2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85: 207-211.
79. Pels, H., Juergens, A., Glasmacher, A., Schulz, H., Engert, A., Linnebank, M. et al. (2009) Early relapses in primary CNS lymphoma after response to poly-chemotherapy without intraventricular treatment: results of a phase II study. J Neurooncol 91: 299-305.
80. Pels, H., Schmidt-Wolf, I.G., Glasmacher, A., Glasmacher, A., Schulz, H., Engert, A. et al. (2003) Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 21: 4489-4495.
81. Peterson, K., Gordon, K.B., Heinemann, M.H. and de Angelis, L.M. ( 1993) The clinical spectrum of ocular lymphoma. Cancer 72: 843-849.
82. Sandor, V., Stark-Vancs, V., Pearson, D., Nussenblat, R., Whitcup, S.M., Brouwers, P. et al. (1998) Phase II trail of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 16: 3000-3006.
83. Schaumburg, H.H., Plank, C.R. and Adams, R.D. ( 1972) The reticulum cell sarcoma-microglioma group of brain tumours. A consideration of their clinical features and therapy. Brain 95: 199-212.
84. Shah, G.D., Yahalom, J., Correa, D.D., Lai, R.K., Raizer, J.J., Schiff, D. et al. (2007) Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 25: 4730-4735.
85. Shapiro, W.R., Young, D.F. and Mehta, B.M. ( 1975) Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N Engl J Med 293: 161-166.
86. Smith, J.R., Rosenbaum, J.T., Wilson, D.J., Doolittle, N.D., Siegal, T., Neuwelt, E.A. et al. (2002 b) Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology 109: 1709-1716.
87. Smith, S.M., Grinblatt, D. and van Besien, K. ( 2002a) Autologous and allogeneic transplantation for aggressive NHL. Cyto therapy 4: 223-240.
88. Soussain, C., Hoang-Xuan, K., Taillandier, L., Fourme, E., Choquet, S., Witz, F. et al. (2008) Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol 26 (15): 2512-2518.
89. Soussain, C., Suzan, F., Hoang-Xuan, K., Cassoux, N., Levy, V., Azar, N. et al. (2001) Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 19: 742-749.
90. Soussain, C. and Hoang-Xuan, K. (2009) Primary central nervous system lymphoma: an update. Curr Opin Oncol 6: 550-558.
91. Strauchen, J.A., Dalton, J. and Friedman, A.H. ( 1989) Chemotherapy in the management of intraocular lymphoma. Cancer 63: 1918-1921.
92. Valluri, S., Moorthy, R.S., Khan, A. and Rao, N.A. ( 1995) Combination treatment of intraocular lymphoma. Retina 15: 125-129.
93. Vassal, G., Valteau, D., Bonnay, M., Patte, C., Aubier, F. and Lemerle, J. ( 1990) Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with non Hodgkin's lymphoma. Pediatr Hematol Oncol 7: 71-77.
94. Weitzner, M.A. and Meyers, C.A. ( 1997) Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psycho-Oncology 6: 169-177.
95. Whitcup, S.M., de Smet, M.D., Rubin, B.I., Palestine, A.G., Martin, D.F., Burnier Jr, M. et al. (1993) Intraocular lymphoma. Clinical and histopathologic diagnosis. Ophthalmology 100: 1399-1406.
96. Wrench, D. and Gribben, J.G. ( 2008) Stem cell transplantation for non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 22: 1051-1079.
97. Yang, S.H., Lee, K.S., Kim, I.S., Hong, J.T., Sung, J.H., Son, B.C. et al. (2009) Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT 6 activation as prognostic determinant. J Neurooncol 92: 65-71.
98. Zhu, J.J., Gerstner, E.R., Engler, D.A., Mrugala, M.M., Nugent, W., Nierenberg, K. et al. (2009) High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 11: 211-215.